XBiotech Inc. (XBIT): Price and Financial Metrics


XBiotech Inc. (XBIT): $13.99

0.19 (+1.38%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add XBIT to Watchlist
Sign Up

Industry: Biotech


Ranked

of 504

in industry

XBIT POWR Grades


  • XBIT scores best on the Value dimension, with a Value rank ahead of 88.7% of US stocks.
  • The strongest trend for XBIT is in Momentum, which has been heading down over the past 52 weeks.
  • XBIT's current lowest rank is in the Momentum metric (where it is better than 4.46% of US stocks).

XBIT Stock Summary

  • XBiotech Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than merely 10.85% of US listed stocks.
  • For XBIT, its debt to operating expenses ratio is greater than that reported by merely 0.5% of US equities we're observing.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 1.02 for XBiotech Inc; that's greater than it is for just 5.71% of US stocks.
  • Stocks that are quantitatively similar to XBIT, based on their financial statements, market capitalization, and price volatility, are MNOV, ACRS, RESN, IONS, and CCXI.
  • XBIT's SEC filings can be seen here. And to visit XBiotech Inc's official web site, go to www.xbiotech.com.

XBIT Valuation Summary

  • XBIT's price/sales ratio is 19.3; this is 70.04% higher than that of the median Healthcare stock.
  • XBIT's price/sales ratio has moved NA NA over the prior 78 months.
  • Over the past 78 months, XBIT's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for XBIT.

Stock Date P/S P/B P/E EV/EBIT
XBIT 2021-08-31 19.3 1.4 -40.3 -9.4
XBIT 2021-08-30 19.5 1.4 -40.9 -9.8
XBIT 2021-08-27 19.4 1.4 -40.7 -9.7
XBIT 2021-08-26 19.2 1.4 -40.2 -9.4
XBIT 2021-08-25 19.1 1.4 -39.9 -9.2
XBIT 2021-08-24 19.2 1.4 -40.1 -9.3

XBIT Growth Metrics

  • Its year over year revenue growth rate is now at 185.2%.
  • Its 4 year net cashflow from operations growth rate is now at -102.23%.
  • The 3 year net cashflow from operations growth rate now stands at 51.84%.
Over the past 49 months, XBIT's revenue has gone up $25,193,000.

The table below shows XBIT's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 25.193 81.698 -12.05
2021-03-31 36.166 -2.667 -13.776
2020-12-31 43.997 -65.149 -11.221
2020-09-30 38.728 -68.504 677.111
2020-06-30 28.179 -80.971 673.487
2020-03-31 12.681 -74.266 674.479

XBIT's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • XBIT has a Quality Grade of D, ranking ahead of 12.96% of graded US stocks.
  • XBIT's asset turnover comes in at 0.071 -- ranking 293rd of 681 Pharmaceutical Products stocks.
  • QLGN, CPHI, and DRNA are the stocks whose asset turnover ratios are most correlated with XBIT.

The table below shows XBIT's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.071 0.391 -0.195
2021-03-31 0.102 0.248 -0.138
2020-12-31 0.124 0.215 -0.116
2020-09-30 0.082 0.166 7.794
2020-06-30 0.070 0.188 10.040
2020-03-31 0.039 0.237 14.665

XBIT Stock Price Chart Interactive Chart >

Price chart for XBIT

XBIT Price/Volume Stats

Current price $13.99 52-week high $20.75
Prev. close $13.80 52-week low $12.20
Day low $13.63 Volume 48,700
Day high $14.16 Avg. volume 85,136
50-day MA $14.74 Dividend yield N/A
200-day MA $16.87 Market Cap 424.99M

XBiotech Inc. (XBIT) Company Bio


XBiotech Inc. is a clinical-stage biopharmaceutical company, engages in discovering and developing “True Human™” monoclonal antibodies for treating various different diseases. The company was founded in 2005 and is based in Austin, Texas.


XBIT Latest News Stream


Event/Time News Detail
Loading, please wait...

XBIT Latest Social Stream


Loading social stream, please wait...

View Full XBIT Social Stream

Latest XBIT News From Around the Web

Below are the latest news stories about XBiotech Inc that investors may wish to consider to help them evaluate XBIT as an investment opportunity.

XBiotech's (NASDAQ:XBIT) investors will be pleased with their fantastic 514% return over the last three years

We think that it's fair to say that the possibility of finding fantastic multi-year winners is what motivates many...

Yahoo | September 14, 2021

Dr. Benjamin Musher to Chair Phase 1-2 Study Evaluating XBiotech''s Natrunix Anti-Cancer Therapy in Pancreatic Cancer

AUSTIN, Texas, Sept. 08, 2021 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT ) ("XBiotech") today announced that Benjamin Musher M.D., will chair XBiotech''s clinical program for pancreatic cancer. The Company is developing a novel cancer drug, Natrunix, to be used in combination with cytotoxic anti-cancer agents. Natrunix specifically blocks a substance that has been shown to stimulate tumor blood supply and break down connective tissue, which can support tumor growth and destruction of healthy tissue. The anti-inflammatory activity of Natrunix is also being evaluated for its ability to reduce the toxicity and injury caused by the cytotoxic anti-cancer agents themselves. XBiotech''s pancreatic cancer program, 1-BETTER, launched with a randomized, double-blind, placebo-controlled Phase...

Benzinga | September 8, 2021

XBiotech Inc.: Dr. Benjamin Musher to Chair Phase 1-2 Study Evaluating XBiotech''s Natrunix Anti-Cancer Therapy in Pancreatic Cancer

AUSTIN, Texas, Sept. 08, 2021 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) ("XBiotech") today announced that Benjamin Musher M.D., will chair XBiotech''s clinical program for pancreatic cancer.

FinanzNachrichten | September 8, 2021

Dr. Benjamin Musher to Chair Phase 1-2 Study Evaluating XBiotechs Natrunix Anti-Cancer Therapy in Pancreatic Cancer

AUSTIN, Texas, Sept. 08, 2021 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) (XBiotech) today announced that Benjamin Musher M.D., will chair XBiotechs clinical program for pancreatic cancer. The Company is developing a novel cancer drug, Natrunix, to be used in combination with cytotoxic anti-cancer agents. Natrunix specifically blocks a substance that has been shown to stimulate tumor blood supply and break down connective tissue, which can support tumor growth and destruction of healthy tissue. The anti-inflammatory activity of Natrunix is also being evaluated for its ability to reduce the toxicity and injury caused by the cytotoxic anti-cancer agents themselves.

Intrado Digital Media | September 8, 2021

Dr. Benjamin Musher to Chair Phase 1-2 Study Evaluating XBiotech’s Natrunix™ Anti-Cancer Therapy in Pancreatic Cancer

AUSTIN, Texas, Sept. 08, 2021 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) (“XBiotech”) today announced that Benjamin Musher M.D., will chair XBiotech’s clinical program for pancreatic cancer. The Company is developing a novel cancer drug, Natrunix™, to be used in combination with cytotoxic anti-cancer agents. Natrunix™ specifically blocks a substance that has been shown to stimulate tumor blood supply and break down connective tissue, which can support tumor growth and destruction of health

Yahoo | September 8, 2021

Read More 'XBIT' Stories Here

XBIT Price Returns

1-mo -9.04%
3-mo -12.40%
6-mo -17.27%
1-year -23.43%
3-year 306.69%
5-year -10.38%
YTD -10.61%
2020 -16.15%
2019 267.42%
2018 28.93%
2017 -61.07%
2016 -6.90%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7978 seconds.